Department of Minimally Invasive Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, P.R. China.
Int J Oncol. 2014 Apr;44(4):1032-40. doi: 10.3892/ijo.2014.2259. Epub 2014 Jan 15.
Among the cytokines linked to inflammation-associated cancer, interleukin (IL)-6 drives many of the cancer 'hallmarks' through downstream activation of the Janus kinase/signal transducer and activator of transcription 3 (JAK/STAT3) signaling pathway. Additionally, dysregulation of the interleukin (IL)-6-mediated JAK/STAT3 signaling pathway is closely related to the development of diverse human solid tumors including colorectal cancer (CRC). On this basis, modulation of the IL-6/JAK/STAT3 signaling pathway is currently being widely explored to develop novel therapies for CRC. The present review details the mechanisms and roles of the IL-6/JAK/STAT3 pathway in CRC, describes current therapeutic strategies, and the search for potential therapeutic approaches to treat CRC.
在与炎症相关的癌症相关的细胞因子中，白细胞介素 (IL)-6 通过下游激活 Janus 激酶/信号转导和转录激活因子 3（JAK/STAT3）信号通路驱动许多癌症“特征”。此外，白细胞介素 (IL)-6 介导的 JAK/STAT3 信号通路的失调与包括结直肠癌 (CRC) 在内的多种人类实体瘤的发展密切相关。在此基础上，目前正在广泛探索调节 IL-6/JAK/STAT3 信号通路的方法，以开发 CRC 的新疗法。本综述详细描述了 IL-6/JAK/STAT3 通路在 CRC 中的机制和作用，描述了当前的治疗策略，并寻找治疗 CRC 的潜在治疗方法。
